Trials / Completed
CompletedNCT01934166
Pharmacokinetic Properties of Nalmefene in Subjects With Renal Impairment and in Healthy Subjects
An Interventional, Single-site, Open-label, Four-group, Single-dose Study Investigating the Pharmacokinetic Properties of Nalmefene in Subjects With Renal Impairment (Mild, Moderate, or Severe) and in Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 32 (actual)
- Sponsor
- H. Lundbeck A/S · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Accepted
Summary
To investigate if renal impairment will have an impact on the pharmacokinetics of nalmefene
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nalmefene 18 mg | One single oral dose of 18 mg |
Timeline
- Start date
- 2013-07-01
- Primary completion
- 2014-08-01
- First posted
- 2013-09-04
- Last updated
- 2016-11-08
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT01934166. Inclusion in this directory is not an endorsement.